Barrons.com1d agoneutral
AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are OpenEven if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
507last 24h
2496last 7d
483● bullish (7d)
253● bearish (7d)
197publishers
PA Media: Money1d agoneutral
Stocks mixed as AstraZeneca merger talk dents FTSE 100The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
MT Newswires4d agoneutral
AbbVie Trims Full-Year Profit Outlook Due to Apogee AcquisitionAbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution
The Wall Street Journal5d agobullish
AbbVie Lowers Outlook to Account for Acquisition as Profit JumpsAbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
GuruFocus.com14d agobullish
Biotech IPOs Surge 55% as AI Listings Lose MomentumStrong biotech returns, major pharma acquisitions and new IPO filings are reshaping the 2026 U.S. listing market.
Motley Fool16d agoneutral
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?There's no need to panic.
Motley Fool35d agobullish
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?AbbVie knows how to plan ahead.
Quartz44d agoneutral
AbbVie acquires Apogee Therapeutics for $10.9 billionThe all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis